Previous Close | 5.6200 |
Open | 5.5800 |
Bid | 0.0000 x 1300 |
Ask | 0.0000 x 800 |
Day's Range | 4.7300 - 5.5800 |
52 Week Range | 4.4000 - 10.9600 |
Volume | |
Avg. Volume | 148,253 |
Market Cap | 237.371M |
Beta (5Y Monthly) | 0.99 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.2700 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 20.86 |
Subscribe to Yahoo Finance Plus to view Fair Value for GLUE
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second half of 2023Received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for MRT-2359 for the treatment of small cell lung cancer (SCLC)Announced development candidate MRT-6160, a novel, highly selective molecular glue degrader of VAV1, with IND submission expected 1H 2024Strong cash position expected to sustain operations into 2025 and enable advancement of p
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors. Dr. Manning is a highly accomplished drug discovery leader in the field of autoimmune and inflammatory diseases. ”Dr. Manning brings extensive knowledge and experience in the field of immunology and inflammation to our B
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...